HMR has successfully completed both early phase and patient trials incorporating bronchoscopy, bronchoalveolar lavage (BAL), and upper GI endoscopy. Adjacent to our wards we have a fully equipped endoscopy suite, with Respiratory Specialist Physicians and Nurse Specialists available to do a wide variety of endoscopy procedures.
We’ve investigated the penetration of novel antibiotic and antiviral compounds (including one against SARS-CoV-2) into bronchial mucosa, epithelial lining fluid, and alveolar macrophages, in both healthy subjects and COPD patients. We’ve published papers in the Journal of Antimicrobial Chemotherapy and the European Journal of Clinical Pharmacology (see links), amongst a wide selection of related respiratory publications.
Penetration of antibiotics into epithelial lining fluid (for extracellular pathogens) and alveolar macrophages (for intracellular organisms) is thought to be a key indicator of potential efficacy, and aids the obtaining of regulatory approval in such indications as hospital-acquired pneumonia, community-acquired pneumonia, and ventilator-associated pneumonia. HMR has a proven record of delivering those data to clients, enabling them to understand lung concentrations and make judgments in relation to dosing, proposed breakpoints, and antimicrobial susceptibility testing. We offer an entire package of clinical trial specialist support, from trial design and regulatory submissions through to clinical trial report and publication.